Clinical trials
Autosomal Recessive Polycystic Kidney Disease clinical trials
Below are recruiting autosomal recessive polycystic kidney disease clinical trials, each written for real people, not researchers. We’re tracking 12 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06601829Recruiting
Liver and kidney disease study in children
This study looks at children with congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. It aims to learn more about these conditions and how they affect children.
SohagAges Any age - NCT04782258RecruitingPhase 3
Testing the safety of tolvaptan in children with ARPKD
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Washington D.C., District of ColumbiaAges 4 weeks–18 years - NCT04338048Recruiting
Study for autosomal dominant polycystic kidney disease
This study enrolls people who have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD), a genetic kidney condition that can cause kidney cysts. It aims to learn about this specific form of the disease so better care is possible for the right patients.
Washington D.C., District of ColumbiaAges Up to 18 years - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06147414Recruiting
Blood test for genetic disorders in pregnancy
This study tests a safer blood test to check for certain genetic disorders during pregnancy, instead of an invasive procedure like amniocentesis. It's for pregnant women who are at risk of passing on a known genetic condition.
ParisAges 18 years+ - NCT07201025Recruiting
MRI study of kidney disease in ARPKD
This study uses MRI scans to track kidney disease progression in children and adults with ARPKD. It aims to better understand how the disease changes over time, which could help improve future care.
Cleveland, OhioAges 6 years+ - NCT01401998Recruiting
Study collecting information from people with ARPKD
This study looks at medical records, imaging, and genetic testing for people with autosomal recessive polycystic kidney disease (ARPKD). It may help researchers better understand the condition and how it affects the liver and kidneys.
Washington D.C., District of ColumbiaAges Up to 18 years - NCT05970172RecruitingPhase 3
Roxadustat for anemia in kids with chronic kidney disease
This study tests roxadustat, a medicine that helps the body make more red blood cells, in children and teens with anemia caused by chronic kidney disease. It may help improve anemia and related blood counts, while also monitoring safety.
BrusselsAges 2–17 - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT02848131Enrolling by invitationPhase 2
Testing dasatinib and quercetin in diabetes-related kidney disease
This study tests whether two medicines (dasatinib and quercetin) can affect “cell aging” in people with chronic kidney disease related to diabetes. You may be asked to take pills for a short period and complete follow-up visits to measure how your body responds.
Jacksonville, FloridaAges 40–80 - NCT07134335RecruitingPhase 2
Study of UBT251 injection for chronic kidney disease
This study tests an investigational injection called UBT251 for people with chronic kidney disease who are overweight. It aims to see if it can reduce protein in the urine and help protect kidney function.
BeijingAges 18–75 - NCT07223502RecruitingPhase 3
Comparing two treatments for high blood pressure and kidney disease
This trial tests if a new treatment combination (finerenone plus a water pill) works better than a standard fixed-dose combination for people with both high blood pressure and chronic kidney disease. It aims to find which option provides more clinical benefit.
Vienna, VirginiaAges 18 years+
Hear when a new Autosomal Recessive Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autosomal recessive polycystic kidney disease?
- Yes. Clin2 currently lists 12 recruiting autosomal recessive polycystic kidney disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autosomal recessive polycystic kidney disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autosomal recessive polycystic kidney disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.